226
Kronik HCV
31.
Bartels DJ, Zhou Y, Zhang EZ ve ark. Natural prevalence of hepatitis C virus
variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-
naive subjects. J Infect Dis 2008; 198:800-807.
32.
Kuntzen T, Timm J, Berical A ve ark. Naturally occurring dominant resistance
mutations to hepatitis C virus protease and polymerase inhibitors in treatment-
naive patients. Hepatology 2008; 48:1769-1778.
33.
Lenz O, Vijgen L, Berke JM ve ark. Virologic response and characterisation of HCV
genotype 2-6 in patients receiving TMC435 monotherapy (study TMC435-C202). J
Hepatol 2013; 58:445-451.
34.
BergeR KL, Lagace L, Triki I ve ark. Viral resistance in hepatitis C virus genotype
1-infected patients receiving the NS3 protease inhibitor Faldaprevir (BI 201335) in a
phase 1b multiple-rising-dose study. Antimicrob Agents Chemother 2013; 57:4928-
4936.
35.
Jacobson I, Dore G, Foster G, ve ark. 2013. Simeprevir (TMC435) with
peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in
treatment-naïve patients: efficacy in difficult-to-treat patient sub-population in
the QUEST-1 and 2 Phase III trials. In: 64th Annual Meeting of the American
Association for the Study of Liver Disease. 1–5 November, 2013, Washington DC,
USA. (Abstract 1122).
36.
Schaefer E, and Chung R. Development of anti-HCV drugs. Thomas H. Lok A,
Locarnini S, Zuckerman AJ (eds). Viral Hepatitis. 4th ed. by UK: John Wiley & Sons:
2014:377-91.
37.
Ranjith-Kumar, C. Cheng Biochemical activities of the HCV NS5B RNA-dependent
RNA polymerase S.L. Tan (Ed.), Hepatitis C Viruses: Genomes and Molecular
Biology (1st ed.), Horizon Bioscience, Norfolk (2006), pp. 293–310.
38.
Gerber L, Welzel TM, Zeuzem S. New therapeutic strategies in HCV: polymerase
inhibitors. Liver Int 2013; 33 Suppl 1:85-92.
39.
Pockros PJ. Non-nucleoside analogue polymerase inhibitors in development. Clin
Liver Dis 2013; 17:123-128.
40.
Lam AM, Espiritu C, Bansal S ve ark. Genotype and subtype profiling of PSI-7977
as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother 2012;
56:3359-3368.
41.
Asselah T. Sofosbuvir-based interferon-free therapy for patients with HCV
infection. J Hepatol 2013; 59:1342-1345.
42.
Gane EJ, Pockros P, Zeuzem S ve ark. Interferon-free treatment with a combination
of mericitabine and danoprevir/r with or without ribavirin in treatment-naive HCV
genotype-1 infected patients J. Hepatol, 56 (Suppl. S2) (2012), pp. S555–6.
43.
Bressanelli S, Tomei L, Rey FA, DE FR. Structural analysis of the hepatitis C virus
RNA polymerase in complex with ribonucleotides. J Virol 2002; 76:3482-3492.
44.
GAO M. Antiviral activity and resistance of HCV NS5A replication complex
inhibitors. Curr Opin Virol 2013; 3:514-520.
45.
Fridell RA, Wang C, Sun JH ve ark. Genotypic and phenotypic analysis of variants
resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor
BMS-790052 in humans: in vitro and in vivo correlations. Hepatology 2011;
54:1924-35.
